Skip to content
LexBuild

Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran

---
identifier: "/us/fr/2010-27010"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran"
title_number: 0
title_name: "Federal Register"
section_number: "2010-27010"
section_name: "Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran"
positive_law: false
currency: "2010-10-26"
last_updated: "2010-10-26"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2010-27010"
document_type: "notice"
publication_date: "2010-10-26"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "75 FR 65642"
fr_volume: 75
docket_ids:
  - "Docket No. FDA-2010-N-0511"
effective_date: "2010-11-05"
fr_action: "Notice."
---

#  Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfanitran

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration (FDA) is withdrawing approval of eight new animal drug applications (NADAs). In a final rule published elsewhere in this issue of the *Federal Register* , FDA is amending the animal drug regulations to remove portions reflecting approval of these NADAs.

**DATES:**

Withdrawal of approval is effective November 5, 2010.

**FOR FURTHER INFORMATION CONTACT:**

John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: *[email protected].*

**SUPPLEMENTARY INFORMATION:**

Fort Dodge Animal Health, a Division of Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d  St., New York, NY 10017 has requested that FDA withdraw approval of the eight NADAs listed in Table 1 of this document.

| NADA No. | Product | Established name of drug(s) |
| --- | --- | --- |
| NADA 11-141 | UNISTAT-2 Type A medicated article | nitromide and sulfanitran |
| NADA 14-250 | NOVASTAT Type A medicated article | aklomide and sulfanitran |
| NADA 34-536 | ALKOMIX Type A medicated article | aklomide |
| NADA 34-537 | NOVASTAT-3 Type A medicated article | aklomide, sulfanitran, and roxarsone |
| NADA 35-388 | NOVASTAT-W Soluble Powder | aklomide and sulfanitran |
| NADA 39-666 | UNISTAT-3 Type A medicated article | nitromide, sulfanitran, and roxarsone |
| NADA 44-015 | TRAMISOL Type A medicated article | levamisole |
| NADA 45-455 | TRAMISOL Type A medicated article | levamisole |

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 11-141, 14-250, 34-536, 34-537, 35-388, 39-666, 44-015, and 45-455, and all supplements and amendments thereto, is hereby withdrawn, effective November 5, 2010.

In a final rule published elsewhere in this issue of the *Federal Register* , FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: October 8, 2010.

Bernadette Dunham,

Director, Center for Veterinary Medicine.